For individuals who need to avoid the broader effects of growth hormone therapy, whether due to metabolic contraindications, cancer concerns, preference for targeted interventions, or athletic testing considerations, AOD-9604 offers a scientifically-validated alternative
These approaches included anti-IGF-1R monoclonal antibodies (mAbs), IGF-1R tyrosine kinase inhibitors (TKIs), IGF-1/2 blocking mAbs, IGF ligand-TRAPs, recombinant IGFBPs and pregnancy-associated plasma protein-A (PAPP-A) inhibition [54,55]
In a further embodiment, when slightly less viscous, or slightly more fluid auris-acceptable pharmaceutical gel formulations are desired, the biocompatible gel portion of the formulation comprises at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, or even at least about 80% or 90% by weight of the compound
Community experiences with DSIP are variable
10.1016/j.heliyon.2023.e21225 11